COVID-19: PeaceHealth is open, with safe virtual and in-person visits.
Learn more about our safety measures and visitor restrictions.

Lung

  • A151216 Adjuvant Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
  • A081105 Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
  • E4512 Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
  • EA5163 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
  • EA5181 Randomized Phase III trial of MEDI4736 (Durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC
  • A081801 Integration of Immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO